Bronchiolitis Obliterans
Conditions
Keywords
Inhalation, Lung Transplantation, Cyclosporine
Brief summary
The purpose of this study is to evaluate long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS) following lung transplantation (LTx) in patients previously enrolled in phase II/III L-CsA clinical trial 12011.201.
Detailed description
This is an uncontrolled extension study open only to patients who completed the Phase II/III core study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy. Determination of long-term safety and efficacy outcome over a maximum of three years will be assessed.
Interventions
DRUGInhalation
Twice daily inhalation for a maximum of three years.
Sponsors
Pari Pharma GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patient has completed the L-CsA clinical trial 12011.201 2. Patient is capable of understanding the purpose and risks of the follow-up study, has been fully informed and has given written informed consent to participate in the study 3. Female patients of child bearing potential must test negative on standard urine pregnancy test prior to continuation and must agree to practice effective birth control during the study 4. Estimated life expectancy \> 6 months 5. Capable of self-administration of medications 6. Patient has stable creatinine levels
Exclusion criteria
1. Patients with ongoing irreversible L-CsA related serious adverse events 2. Patients with known hypersensitivity for ciclosporin A 3. Patient intends to participate in another IMP clinical trial other than listed in the inclusion criteria 4. Patient receives mechanical ventilation 5. Patients underwent pulmonary re-transplantation 6. Patient is a pregnant or breast-feeding woman 7. Patient is unlikely to comply with visits, inhalation procedures or spirometric measurements scheduled in the protocol 8. Patient receives any systemic or topical Rosuvastatin 9. Patient has been previously enrolled in this study 10. Patient with malignancy diagnosed during study 12011.201 (with the exception of skin cancer) 11. Documented respiratory infections unless on appropriate antimicrobial therapy with evidence of clinical response 12. Patient is not eligible to continue IMP inhalation according to the Investigator's discretion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS) | 3 years | Safety will be assesses by the numbers of treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) and overall rate of mortality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Long-term efficacy outcome over a maximum of three years of patients previously enrolled in phase II/III L-CsA clinical trial 12011.201 | 3 years | Efficacy will be assessed mainly for the following efficacy endpoints: * BOS-free survival * Incidence of BOS * Pulmonary function |
Countries
Germany
Outcome results
None listed